Adlai Nortye Group Ltd. ANL
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- +623.94%
- 1 year
- +563.23%
- Market cap
- 662.01M
- Revenue (ttm)
- 18.06M
- Profit margin
- -124.77%
- EPS (ttm)
- -0.66
- Shares out
- 58.73M
- Forward P/E
- -53.08
- YTD return
- +623.94%
- 1-year return
- +563.23%
- Volume
- 531.01K
- Avg volume
- 221.25K
- Open
- 9.77
- Previous close
- 9.68
- Day's range
- 9.43 – 10.64
- 52-week range
- 0.88 – 16.60
- Beta
- 1.11
- Analysts
- Strong Buy
- Price target
- 29.50 (+187.0%)
- Earnings date
- Mar 3, 2027
2Y +7.76 (+307.94%)
Key statistics
- Enterprise value
- 792.70M
- PEG ratio
- 0.00
- Price / sales
- 55.71
- Price / book
- 4.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.45M
- Total cash
- 232.82M
- Total debt
- 26.70M
- Return on equity
- -20.23%
- Short % of float
- 7.59%
- 50-day average
- 14.47
- 200-day average
- 10.61
Analyst view
Consensus: strong buy
- Target (low)
- 20.00
- Target (mean)
- 29.50
- Target (high)
- 49.00
- Strong buy0
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 3, 2027
Expected Mar 3, 2027. Consensus EPS estimate 0.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 3, 2027 | Sep 30, 2026 | -0.15237 | — | — | — |
| Aug 14, 2026 | Jun 30, 2026 | -0.05744 | -0.04 | +0.02 | +30.36% |
| Apr 29, 2026 | Mar 31, 2026 | -0.18 | — | — | — |
| Apr 10, 2026 | Dec 31, 2025 | -0.18 | -0.81 | -0.63 | -350.00% |
| Dec 29, 2025 | Sep 30, 2025 | -0.18 | -0.18 | 0.00 | 0.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.18 | -0.18 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 2026 | Jefferies | init | — | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 22, 2026 | Cantor Fitzgerald | init | — | Overweight |
| May 28, 2026 | Oppenheimer | init | — | Outperform |
| May 14, 2026 | Jones Trading | init | — | Buy |
| Apr 20, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Adlai Nortye Group Ltd.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- Website
- adlainortye.com
News
Adlai Nortye Group Reveals Oral Presentation For AN4035 Program Update At the Upcoming 38th EORTC-NCI-AACR Symposium 
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday 
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody 
Jefferies Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $31 - HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target
Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M - Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, A Pan-RAS(ON) Inhibitor 
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Oppenheimer Initiates Coverage On Adlai Nortye with Outperform Rating, Announces Price Target of $32
Your note
Sign in to keep a note on ANL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JI PING | Director | Sale | Sep 29, 2026 | 121,453 |
| LU YANG | Chief Executive Officer | Sale | May 12, 2026 | 99,990 |
| YE XIAOFENG | Chief Financial Officer | Sale | Aug 25, 2026 | 147,757 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 6.77% | 3,978,229 | 62.14M | Jun 29, 2026 |
| Venrock Adviser, LLC | 5.47% | 3,212,731 | 50.18M | Jun 29, 2026 |
| Balyasny Asset Management LP | 5.21% | 3,061,668 | 47.82M | Jun 29, 2026 |
| Point72 Asset Management, L.P. | 3.64% | 2,140,664 | 33.44M | Jun 29, 2026 |
| MPM Bioimpact LLC | 3.30% | 1,936,291 | 30.24M | Jun 29, 2026 |
| Perceptive Advisors Llc | 3.05% | 1,793,190 | 28.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.22% | 718,747 | 11.23M | Jun 29, 2026 |
| Tema ETF Trust-Tema Oncology ETF | 0.08% | 44,354 | 692.81K | May 30, 2026 |
| ETFis Series Trust I-Virtus Biotech Clinical Trials ETF | 0.05% | 30,117 | 470.43K | Jul 30, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.03% | 17,020 | 265.85K | Jul 30, 2026 |
| ProFunds-UltraChina ProFund | 0.00% | 1,156 | 18.06K | Jul 30, 2026 |
| Gabelli Healthcare & WellnessRx Trust | 0.00% | 600 | 9.37K | Sep 29, 2026 |